Regeneron Pharmaceuticals | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
AbbVie USD 10.71B 458M 2024-12
Agios Pharmaceuticals USD 9.47M 1.29M 2024-12
Alnylam Pharmaceuticals USD 490.35M 75.33M 2024-12
Amgen USD 5.97B 781M 2024-12
Astellas Pharma JPY 418.89B 39.08B 2024-12
AstraZeneca USD 12.17B 1.06B 2024-12
Biogen USD 1.87B 44.1M 2024-12
BioMarin Pharmaceutical USD 611.17M 53.89M 2024-12
Bristol-Myers Squibb USD 9.13B 94M 2024-12
Eli Lilly USD 11.13B 1.86B 2024-12
Gilead Sciences USD 5.99B 17M 2024-12
GlaxoSmithKline GBP 5.56B 57M 2024-12
Incyte USD 1.1B 38.34M 2024-12
Ionis Pharmaceuticals USD 222.75M 90M 2024-12
J&J USD 14.6B 816M 2025-03
Kyowa Hakko Kirin JPY 95.29B 1.76B 2024-09
Merck USD 11.92B 852M 2024-12
Moderna USD 420M 1.14B 2024-12
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Novartis USD 10.23B 294M 2024-12
Novartis USD 10.24B 313M 2024-12
Pfizer USD 12.11B 718M 2024-12
Regeneron Pharmaceuticals USD 3.22B 1.88B 2024-12
Roche Holding CHF 11.69B 48M 2024-12
Sanofi EUR 5.36B 4.71B 2024-12
Sarepta Therapeutics USD 526.11M 150.63M 2024-12
Teva Pharmaceutical Industries USD 2.12B 85M 2024-12
Ultragenyx Pharmaceutical USD 147.98M 29.51M 2024-12
United Therapeutics USD 660M 5.8M 2024-12
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12



Regeneron Pharmaceuticals Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Apr 2025.